Literature DB >> 18068774

Enantioselective analysis of mirtazapine and its two major metabolites in human plasma by liquid chromatography-mass spectrometry after three-phase liquid-phase microextraction.

Fernando José Malagueño de Santana1, Pierina Sueli Bonato.   

Abstract

A three-phase liquid-phase microextraction (LPME) method using porous polypropylene hollow fibre membrane with a sealed end was developed for the extraction of mirtazapine (MRT) and its two major metabolites, 8-hydroxymirtazapine (8-OHM) and demethylmirtazapine (DMR), from human plasma. The analytes were extracted from 1.0 mL of plasma, previously diluted and alkalinized with 3.0 mL 0.5 molL(-1) pH 8 phosphate buffer solution and supplemented with 15% sodium chloride (NaCl), using n-hexyl ether as organic solvent and 0.01 moLL(-1) acetic acid solution as the acceptor phase. Haloperidol was used as internal standard. The chromatographic analyses were carried out on a chiral column, using acetonitrile-methanol-ethanol (98:1:1, v/v/v) plus 0.2% diethylamine as mobile phase, at a flow rate of 1.0 mLmin(-1). Multi-reaction monitoring (MRM) detection was performed by mass spectrometry (MS-MS) using a triple-stage quadrupole and electrospray ionization interface operating in the positive ion mode. The mean recoveries were in 18.3-45.5% range with linear responses over the 1.25-125 ngmL(-1) concentration range for all enantiomers evaluated. The quantification limit (LOQ) was 1.25 ngmL(-1). Within-day and between-day assay precision and accuracy (2.5, 50 and 100 ngmL(-1)) showed relative standard deviation and the relative error lower than 11.9% for all enantiomers evaluated. Finally, the method was successfully used for the determination of mirtazapine and its metabolite enantiomers in plasma samples obtained after single drug administration of mirtazapine to a healthy volunteer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18068774     DOI: 10.1016/j.aca.2007.10.037

Source DB:  PubMed          Journal:  Anal Chim Acta        ISSN: 0003-2670            Impact factor:   6.558


  3 in total

1.  Determination of mirtazapine in spiked human plasma and tablets by first derivative spectrofluorimetric method.

Authors:  Rasha M Youssef
Journal:  Saudi Pharm J       Date:  2010-01-06       Impact factor: 4.330

2.  Behavioral and developmental changes in rats with prenatal exposure of mirtazapine.

Authors:  Jasmita Sahoo; Ashok K Pattnaik; Nibha Mishra
Journal:  Sci Pharm       Date:  2010-06-30

3.  A Rapid and Sensitive HPLC-Fluorescence Method for Determination of Mirtazapine and Its two Major Metabolites in Human Plasma.

Authors:  Hoda Lavasani; Mario Giorgi; Behjat Sheikholeslami; Mohammadhasan Hedayati; Mohammad Reza Rouini
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.